Drugs / galeterone
Trials 5 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02729376 | Mar → Apr 2016 | — | LTN PHARMACEUTICALS, INC. | Completed | No outcome recorded |
| Phase 1 | NCT00959959 | Oct 2009 → Aug 2011 | prostate cancer | LTN PHARMACEUTICALS, INC. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT04098081 | Dec 2019 → Dec 2026 expected | pancreatic neoplasm | University of Maryland, Baltimore | Active not recruiting | No outcome recorded |
| Phase 2 | NCT01709734 | Dec 2012 → Sep 2016 | prostate cancer | LTN PHARMACEUTICALS, INC. | Terminated | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT02438007 | Jun 2015 → Jul 2016 | prostate cancer | LTN PHARMACEUTICALS, INC. | Terminated | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Galeterone | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02438007 ↗ |
| Known as | Galeterona | ChEMBL registry synonym — accepted as the source's own label CHEMBL2105738 ↗ |
| Known as | TOK-001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00959959 ↗ |
| Known as | VN 124 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2105738 ↗ |
| Known as | VN/124-1 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2105738 ↗ |
| Action | Inhibit | “Galeterone is an androgen receptor inhibitor” NCT04098081 ↗ |
| Modality | Small molecule | — CHEMBL2105738 ↗ |
| Route | Oral | “galeterone tablets once daily PO for three months + extension” NCT01709734 ↗ |
| Target | AR | “Androgen Receptor antagonist” CHEMBL2105738 ↗ |
| Target | CYP17A1 | “Cytochrome P450 17A1 inhibitor” CHEMBL2105738 ↗ |